loading page

Benefits of Early Combination Antiviral Treatment Containing Favipiravir for COVID-19 in Thailand
  • +8
  • Kulkanya Chokephaibulkit,
  • Narumol Sawanpanyalert,
  • Rujipas Sirijatuphat,
  • Piamlarp Sangsayunh,
  • Poj Intalapaporn,
  • Opass Putcharoen,
  • Weerawat Manosuthi,
  • Nattawan Palavutitotai,
  • Worawan Samritmanoporn,
  • Apatcha Pungjitprapai,
  • Alan Maleesatharn
Kulkanya Chokephaibulkit
Mahidol University Faculty of Medicine Siriraj Hospital

Corresponding Author:[email protected]

Author Profile
Narumol Sawanpanyalert
Royal Thai Government Ministry of Public Health
Author Profile
Rujipas Sirijatuphat
Mahidol University Faculty of Medicine Siriraj Hospital
Author Profile
Piamlarp Sangsayunh
Central Chest Institute of Thailand
Author Profile
Poj Intalapaporn
Rajavithi Hospital
Author Profile
Opass Putcharoen
Chulalongkorn University Faculty of Medicine
Author Profile
Weerawat Manosuthi
Bamrasnaradura Infectious Disease Institute
Author Profile
Nattawan Palavutitotai
Lerdsin Hospital
Author Profile
Worawan Samritmanoporn
Nopparat Rajathanee Hospital
Author Profile
Apatcha Pungjitprapai
Charoenkrung Pracharuk Hospital
Author Profile
Alan Maleesatharn
Mahidol University Faculty of Medicine Siriraj Hospital
Author Profile


We report the clinical outcomes following implementation of initial COVID-19 treatment guidelines in Thailand. A composite poor outcome was defined as death, ICU admission, requiring intubation, or high-flow oxygen. 744 COVID-19 patients (48.8% male) were included, median (IQR) age was 37 (27-48) years [8.4% >60 years] and 21.4% had pneumonia at admission. Admission <4 days from symptom onset had a reduced risk of poor outcome. In a subgroup analysis, favipiravir use reduced the risk of a poor outcome for patients admitted <4 days from symptom onset (OR 0.320 (0.152-0.662), P=0.003). Thai guidelines now include favipiravir to treat all symptomatic COVID-19 patients.